EUVIMEDScopri EUVIMED
Crossref

Combinatorial metabolic engineering of Bacillus subtilis for menaquinone‐7 biosynthesis

Xian Sun, Xinyu Bi, Guyue Li, Shixiu Cui, Xianhao Xu, Yanfeng Liu, Jianghua Li, Guocheng Du, Xueqin Lv, Long Liu

Biotechnology and Bioengineering · 2024-10 · 121 (10) · 3338-3350

DOI: 10.1002/bit.28800 ↗

At a glance

Journal article in Biotechnology and Bioengineering, published online on 2024-07-04. Written by Xian Sun and 9 co-authors. Institution: Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, Jiangnan University, Wuxi, China. Major MEDLINE topics: Bacillus subtilis, Metabolic Engineering, Vitamin K 2. Cited 19 times so far (Crossref); 42 references. Funded by: National Natural Science Foundation of China.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Menaquinone‐7 (MK‐7), a form of vitamin K2, supports bone health and prevents arterial calcification. Microbial fermentation for MK‐7 production has attracted widespread attention because of its low cost and short production cycles. However, insufficient substrate supply, unbalanced precursor synthesis, and low catalytic efficiency of key enzymes severely limited the efficiency of MK‐7 synthesis. In this study, utilizing Bacillus subtilis BSAT01 (with an initial MK‐7 titer of 231.0 mg/L) obtained in our previous study, the glycerol metabolism pathway was first enhanced to increase the 3‐deoxy‐arabino‐heptulonate 7‐phosphate (DHAP) supply, which led to an increase in MK‐7 titer to 259.7 mg/L. Subsequently, a combination of knockout strategies predicted by the genome‐scale metabolic model etiBsu1209 was employed to optimize the central carbon metabolism pathway, and the resulting strain showed an increase in MK‐7 production from 259.7 to 318.3 mg/L. Finally, model predictions revealed the methylerythritol phosphate pathway as the major restriction pathway, and the pathway flux was increased by heterologous introduction (Introduction of Dxs derived from Escherichia coli ) and fusion expression (End‐to‐end fusion of two enzymes by a linker peptide), resulting in a strain with a titer of 451.0 mg/L in a shake flask and 474.0 mg/L in a 50‐L bioreactor. This study achieved efficient MK‐7 synthesis in B. subtilis , laying the foundation for large‐scale MK‐7 bioproduction.

Subjects

MeSH terms (MEDLINE)

Bacillus subtilisMetabolic EngineeringVitamin K 2Metabolic Networks and Pathways

Author keywords

Bacillus subtiliscombinatorial metabolic engineeringenzyme engineeringetiBsu1209menaquinone‐7

Substances

Vitamin K 2menaquinone 7

Authors and institutions

  • Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, Jiangnan University, Wuxi, China.
  • Science Center for Future Foods, Jiangnan University, Wuxi, China.
  • Food Laboratory of Zhongyuan, Jiangnan University, Wuxi, China.
  • Richen Bioengineering Co., Ltd., Nantong, China.
  • Jiaxing Institute of Future Food, Jiaxing, China.

Funding

  • National Natural Science Foundation of China

Cite

APA

Sun, X., Bi, X., Li, G., Cui, S., Xu, X., Liu, Y., Li, J., Du, G., Lv, X., & Liu, L. (2024). Combinatorial metabolic engineering of Bacillus subtilis for menaquinone‐7 biosynthesis. Biotechnology and Bioengineering, 121(10), 3338-3350. https://doi.org/10.1002/bit.28800

Vancouver

Sun X, Bi X, Li G, Cui S, Xu X, Liu Y, et al. Combinatorial metabolic engineering of Bacillus subtilis for menaquinone‐7 biosynthesis. Biotechnology and Bioengineering. 2024;121(10):3338-3350. doi:10.1002/bit.28800

BibTeX
@article{Sun2024,
  author = {Sun, Xian and Bi, Xinyu and Li, Guyue and Cui, Shixiu and Xu, Xianhao and Liu, Yanfeng and Li, Jianghua and Du, Guocheng and Lv, Xueqin and Liu, Long},
  title = {Combinatorial metabolic engineering of Bacillus subtilis for menaquinone‐7 biosynthesis},
  journal = {Biotechnology and Bioengineering},
  year = {2024},
  volume = {121},
  number = {10},
  pages = {3338--3350},
  doi = {10.1002/bit.28800}
}
Start for free →